We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





POC Electrical Sensing-Based Blood Testing Technology Unveiled at ADLM 2024

By LabMedica International staff writers
Posted on 30 Jul 2024
Print article
Image: The Chronus Health platform is being demonstrated at ADLM 2024 (Photo courtesy of Chronus Health)
Image: The Chronus Health platform is being demonstrated at ADLM 2024 (Photo courtesy of Chronus Health)

Chronus Health (Fremont, CA, USA) is showcasing its innovative platform powered by electrical sensing-based blood testing technology at the ADLM 2024 conference taking place in Chicago from July 28 to August 1.

Chronus has developed the first-of-a-kind electrical sensing-based, real-time blood testing system for use in urgent care centers, skilled nursing facilities, infusion centers, retail clinics, as well as primary care and specialty clinics. This technology will reduce the time to diagnosis and lower overall healthcare costs since blood samples are analyzed on-site rather than sent to central labs for analysis. Chronus’ platform can uniquely support cell counting, chemistry assays (electrolytes, small molecules, and proteins), and immunoassays (proteins). This comprehensive solution, often regarded as the “holy grail” of diagnostics, has remained elusive until now, as past attempts to miniaturize existing technologies have lacked technical feasibility and cost-effectiveness.

The world’s first real-time electrical blood test system offers significant advantages in cost, size, and simplicity through the use of electrical sensors that facilitate miniaturization and reduce complexity. By leveraging a proprietary electrical sensing approach that integrates microfluidic sensors, machine learning, and aptamers, Chronus is poised to be the first to successfully deliver a platform capable of testing multiple blood panels outside the central lab setting. With 60% of all blood tests conducted outside hospitals, the company is at the forefront of providing fast and accurate blood testing at the point of care, at a lower price point.

“No one likes waiting for blood test results – neither doctors nor patients or their families,” said Caesar Djavaherian, MD, Co-Founder and Chief Clinical Innovation Officer of Carbon Health. “Now we have a technology that can cost-effectively provide results at the point of care, leading to better patient outcomes and increased provider satisfaction. We look forward to launching a clinical trial using the Chronus system soon.”

“We are creating a new era for point-of-care testing, with a platform slated to revolutionize the diagnostics industry,” said Anand Parikh, CEO and Co-Founder of Chronus Health. “The foundation of processing lab work has remained the same for decades, and just as other industries have benefited from the innovation in electrical technology, so too will healthcare.”

Related Links:
Chronus Health

New
Gold Member
LEISHMANIA Test
LEISHMANIA ELISA
New
Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
New
MTHFR Mutation Test
REALQUALITY THROMBO MTHFR
New
Gold Member
Legionella Pneumophila Test
Legionella Pneumophila ELISA

Print article

Channels

Molecular Diagnostics

view channel
Image: Umbilical cord blood biomarkers may improve preterm infant care (Photo courtesy of Shutterstock)

Umbilical Cord Blood Test Could Identify Preterm Infants at Risk for Medical Complications

Advancements in medical technology and neonatology have significantly improved the care of prematurely born infants. However, these infants still face heightened risks for medical complications, such as... Read more

Immunology

view channel

3D Bioprinted Gastric Cancer Model Uses Patient-Derived Tissue Fragments to Predict Drug Response

Tumor heterogeneity presents a major obstacle in the development and treatment of cancer therapies, as patients' responses to the same drug can differ, and the timing of treatment significantly influences prognosis. Consequently, technologies that predict the effectiveness of anticancer treatments are essential in minimizing... Read more

Microbiology

view channel
Image: The Cytovale System isolates, images, and analyzes cells (Photo courtesy of Cytovale)

Rapid Sepsis Diagnostic Test Demonstrates Improved Patient Care and Cost Savings in Hospital Application

Sepsis is the leading cause of death and the most expensive condition treated in U.S. hospitals. The risk of death from sepsis increases by up to 8% for each hour that treatment is delayed, making early... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.